Imagerolan

Imatinib, the active ingredient in Imagerolan, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in appropriate patients.

GNH USA supplies Imagerolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imagerolan is a tyrosine kinase inhibitor used in hematologic and solid‑tumor malignancies that depend on BCR‑ABL, c‑KIT or PDGFR signaling. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by targeting the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor (GIST): inhibits KIT‑driven tumor growth, leading to disease control.

Adverse reactions may occur with any dose of Imagerolan.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: occasional painful muscle tightening. - Fatigue: generalized tiredness. - Diarrhea: loose stools, usually self‑limiting. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Myelosuppression: severe neutropenia, anemia or thrombocytopenia. - Cardiac toxicity: rare cases of congestive heart failure or QT prolongation.

Before initiating Imagerolan, clinicians should assess baseline organ function and monitor patients regularly. - Monitor blood counts: perform routine CBC to detect cytopenias. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: obtain ECG if risk factors for QT prolongation exist. - Avoid use in patients with known hypersensitivity to imatinib or its excipients. - Store at below 25°C: keep in the original pack, protect from moisture.

Imagerolan can interact with several drug classes; careful management is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure and toxicity. - CYP3A4 inducers (e.g., rifampin): may lower plasma levels, reducing efficacy. - Antacids containing aluminum or magnesium: may impair oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect; monitor INR. - QT‑prolonging agents: combined use can increase arrhythmia risk; observe ECG. - Live vaccines: immunosuppression may diminish vaccine response; consider timing.